

19 **ABSTRACT**

20 Background

21 New noninvasive and affordable molecular approaches that will complement current practices and
22 increase the accuracy of PD diagnosis are urgently needed. CircRNAs are highly stable non-coding
23 RNAs that accumulate with aging in neurons and are increasingly shown to regulate all aspects of
24 neuronal development and function.

25 Objectives

26 The aims of the present study were to identify differentially expressed circRNAs in PBMCs of
27 idiopathic PD patients and explore the competing endogenous RNA networks affected.

28 Methods

29 Eighty-seven circRNAs were initially selected based on relatively high gene expression in the
30 human brain. Over half of these were readily detectable in PBMCs using RT-qPCR. Comparative
31 expression analysis was then performed in PBMCs from sixty controls and sixty idiopathic
32 subjects with PD.

33 Results

34 Six circRNAs derived from MAPK9, HOMER1, SLAIN1, DOP1B, REPS1, and PSEN1
35 transcripts were significantly downregulated in PD patients. The classifier that best distinguished
36 PD consisted of four circRNAs with an AUC of 0.84. CLIP-Seq data revealed that the RNA
37 binding proteins bound by most of the deregulated circRNAs include the neurodegeneration-
38 associated FUS, TDP43, FMR1 and ATXN2. MicroRNAs predicted to be sequestered by most
39 deregulated circRNAs had the GOslim categories ‘Protein modification’, ‘Transcription factor
40 activity’ and ‘Cytoskeletal protein binding’ mostly enriched.

41 Conclusions

42 This is the first study that identifies circRNAs deregulated in the peripheral blood of PD patients.
43 They may serve as diagnostic biomarkers and since they are highly expressed in the brain and are
44 derived from genes with essential brain functions, they may also hint on the PD pathways affected.

45

46 **INTRODUCTION**

47 The diagnosis of PD is currently based on clinical diagnostic criteria and neuroimaging and is
48 monitored by rating scales related to motor and non-motor features ¹. Rating scales are frequently
49 subjective and influenced by periodic fluctuations in symptoms and effective symptomatic
50 therapies, while neuroimaging techniques, such as DAT-SPECT, offer a quantifiable measure of
51 disease progression but are limited by practicality and costs ². In addition, protein biomarkers, such
52 as those based on alpha-synuclein (SNCA) and dopamine metabolic products have yielded mixed
53 results, do not reflect disease progression and require an invasive lumbar puncture ³.

54 Circular RNAs (circRNAs) are a newly recognized class of single-stranded regulatory RNAs that
55 are formed by head-to-tail splicing in which a downstream 5' splice site is covalently connected
56 to an upstream 3' splice site of an RNA molecule. The result is an enclosed non-polyadenylated
57 circular transcript ⁴⁻⁶. Due to the lack of free ends, that are normally targeted by 3' and 5'
58 exoribonucleases, circRNAs are extremely stable with half-life of more than 48 h compared to
59 approximately 6 h of linear transcripts ^{7, 8}. There are different subtypes of circRNAs including
60 exonic, intronic and exo-intronic. Exonic circRNAs are mostly localized in the cytoplasm where
61 they act as sponges for microRNAs (miRNAs) and RNA-binding proteins (RBPs), thus inhibiting
62 their interaction with mRNA targets ^{4, 9-11}. In contrast, intronic or exo-intronic circRNAs are mostly
63 localized in the nucleus and have few or no binding sites for miRNAs; instead they function to
64 control transcription ^{12, 13}. Interestingly, the co-transcriptional biogenesis of circRNAs has also

65 been shown to reduce linear host mRNA levels and change downstream splice-site choice in some
66 mRNAs^{11, 14, 15}.

67 CircRNAs are widely conserved and more abundant in the brain than in any other tissue¹⁶ with
68 many being expressed in an organ-specific manner, along with their host genes which are enriched
69 with tissue-specific biological functions¹⁷. For instance, brain circRNA host genes are enriched in
70 neurotransmitter secretion, synaptic activities and neuron maturation¹⁷. Importantly, however,
71 they are regulated independently from their linear counterparts^{16, 18} with 60% of CNS circRNAs
72 being upregulated throughout development, especially during synaptogenesis, while only 2% of
73 their linear isoforms show this tendency¹⁷.

74 Recent studies revealed the deregulation of circRNAs in neurodegenerative diseases and
75 neuropsychiatric disorders (reviewed in¹⁹). Furthermore, several brain-enriched circRNAs have
76 been associated with pathogenetic processes of neurodegeneration. For instance, CDR1as (ciRS-
77 7), a highly abundant circRNA in the brain, is downregulated in the brain of patients with AD²⁰.
78 This circRNA contains 63 binding sites for miR-7 and therefore it is acting as an efficient sponge
79 for it⁴. Importantly, critical proteins for the neurodegeneration processes such as the ubiquitin
80 protein ligase A (UBE2A), which catalyses the proteolytic clearing of toxic amyloid peptides in
81 AD, and SNCA, which accumulates in PD/AD, are both targets of miR-7^{21, 22}. More recently,
82 another circRNA, circSLC8A1, was found to increase in the substantia nigra of individuals with
83 PD and in cultured cells exposed to the oxidative stress-inducing agent paraquat²³. Importantly,
84 circSLC8A1 carries seven binding sites for miR-128, an abundant and brain-restricted miRNA
85 that governs neuronal excitability and motor behavior²⁴⁻²⁷.

86 Peripheral blood mononuclear cells (PBMCs) inherit the same genetic information as brain cells
87 and are armed with abundant signaling pathways that respond to pathological changes. Multiple

88 studies have shown that genome-wide transcriptional and alternative splicing profiles in peripheral
89 blood parallel changes in gene expression in the brain, reflecting broad molecular and cellular
90 impairments²⁸⁻³³. Therefore, PBMCs provide a powerful and minimally-invasive tool for the
91 identification of novel targets for neurodegeneration research. Considering that circRNAs a) are
92 abundant in the brain modulating gene expression *en masse*, b) are stable, c) do not get modified
93 like proteins, hence levels directly correlate with activity and d) can be accurately quantified by
94 routine and fast laboratory methods, such as RT-qPCR, suggests that they not only represent
95 excellent candidate biomarkers but also important constituents of the pathophysiological processes
96 implicated in neurological diseases. The purpose of this study was to identify differentially
97 expressed brain-enriched circRNAs in PBMCs from patients with idiopathic PD (iPD) and
98 pinpoint competing endogenous (ceRNA) networks.

99

100 **MATERIAL AND METHODS**

101 Figure 1 provides a schematic representation of the workflow.

102

103 **Study population**

104 The present study included 60 iPD patients and 60 healthy individuals in two separate cohorts.
105 Patients were assessed with brain magnetic resonance imaging (MRI) or computed tomography
106 (CT) and no relevant brain vascular lesions explaining the clinical phenotype were detected. The
107 control group included spouses or unrelated companions of patients who had no known
108 neurological disease, comorbidities or PD family history. Individuals with concurrent malignant
109 tumours, psychiatric disorders, collagen diseases, endocrine and cardiovascular diseases, or
110 infections were excluded from this study, since these conditions are expected to alter the

111 expression profile of transcripts. Patients affected by atypical parkinsonism were also excluded.
112 All patients and controls were recruited from the National and Kapodistrian University of Athens’
113 First Department of Neurology at Eginition hospital. PD was diagnosed by two neurologists
114 according to Postuma et al., criteria ¹. In all cases, essential demographic and clinical information,
115 including the study questionnaire for motor and non-motor manifestations of the disease, rating
116 scales [Hoehn & Yahr (H&Y) stage, mini-mental state examination (MMSE, cognitive impairment
117 score <26 ³⁴), Unified Parkinson's Disease Rating Scale part III (UPDRS III) in the on or off state]
118 were collected and documented. The demographic and clinical features of patients and controls
119 are summarized in Table 1. Levodopa equivalent daily dose (LEDD) was calculated for the patient
120 group according to Tomlinson et al., criteria ³⁵. The Eginition hospital and BRFAA ethics
121 committees approved the study and all participants provided written consent.

122

123 **Isolation of peripheral blood mononuclear cells**

124 PBMCs were isolated from whole blood by employing density-gradient centrifugation using the
125 Biocoll Separating Solution according to manufacturer’s instructions (Biochrom AG).

126

127 **Total RNA extraction and RT-qPCR analysis**

128 Total RNA extraction was performed using the RNAzol[®]-RT reagent according to manufacturer’s
129 instructions (Molecular Research Center, MRC). To improve the yield of the small RNA fraction,
130 a polyacryl carrier (PC152, MRC) was added during the extraction method. Reverse transcription
131 reactions were performed in triplicate for every sample. Similarly, qPCR was performed in
132 triplicate on the Roche Lightcycler[®] 96 using the SYBR FAST Universal 2X qPCR Master Mix
133 from Kapa Biosystems. For the differential expression analysis, we selected only those circRNAs

134 that were detected in PBMCs with a crossing threshold (Ct) value below 30, for improved detection
135 accuracy. All primers span the splice junction. *U6* and *GAPDH* were used as reference genes. The
136 relative expression level of circRNAs was calculated using the $2^{-\Delta\Delta C_t}$ method between age- and
137 gender- matched counterparts. Primer sequences can be found in Suppl. Table 1.

138

139 **CircRNA selection process**

140 Eighty-seven circRNAs were carefully selected by cross-examining the data from three genome-
141 wide surveys^{4, 18, 36}. We chose circRNAs that had high expression in the brain (Rybak-Wolf score
142 above ~1,000) and low or no expression in other tissues. The host gene expression was also taken
143 into account in the selection process. Initially, based on GTEx portal expression data, circRNAs
144 for which host transcripts were specifically expressed in the brain were selected. However, we
145 found that many circRNAs derived from these transcripts were not readily detectable in PBMCs.
146 We, therefore, widened the analysis to host transcripts that are brain- or at least cerebellum-
147 enriched (i.e. not exclusively expressed in the brain). Last, we included six brain-abundant
148 circRNAs deriving from host transcripts with low expression in the brain (UBXN7_circ_0001380,
149 TMEM138_circ_0002058, ZNF292_circ_0004058, HAT1_circ_0008032,
150 ZFAND6_circ_0000643, UIMC1_circ_0001558) and eight circRNAs that are hosted by brain-
151 relevant transcripts that have been found deregulated in AD (CORO1C_circ_0000437,
152 WDR78_circ_0006677, PHC3_circ_0001359, SLAIN2_circ_0126525)³⁷ and autism
153 (FAM120A_circ_0001875, CSNK1G3_circ_0001522, VMP1_circ_0006508,
154 SMARCA5_circ_0001445)³⁸. For the list of circRNAs analyzed see Suppl. Tables 1 and 2.

155

156 **CircRNA target network**

157 The interactions of the differentially expressed circRNAs with miRNAs and RBPs were identified
158 by obtaining data from the Circular RNA Interactome (CircInteractome) and Interactional
159 Database of Cancer-Specific CircRNAs (IDCSC) databases, respectively ^{39, 40}. CircInteractome
160 utilizes the TargetScan algorithm to predict microRNA response elements (MREs, ie miRNA-
161 binding sites) while IDCSC hosts circRNA cross-linking immunoprecipitation (CLIP)-Seq data
162 for the different RBPs extracted from StarBase database ⁴¹. The circRNA-miRNA and circRNA-
163 RBP interactomes were then manually curated using the Cytoscape v.3.8.0 platform.

164

165 **miRNA pathway analysis**

166 The DIANA mirPath v.3 software suite was used to identify miRNA-regulated pathways. This
167 software renders possible the functional annotation of miRNAs using standard hypergeometric
168 distributions, unbiased empirical distributions and meta-analysis statistics ⁴². Here, predicted
169 targets from DIANA microT-CDS algorithm with high quality experimentally supported
170 interactions were used to identify KEGG molecular pathways, as well as GO terms targeted by
171 each miRNA. The combinatorial effect of deregulated miRNAs was identified by simultaneously
172 selecting multiple miRNAs in the software. The default values (p-value threshold 0.05, microT-
173 CDS threshold 0.8, FDR correction option ticked) were used for the analysis.

174

175 **Statistical analysis**

176 Statistical analysis was performed using GraphPad PRISM v5.0 and R v3.5.3. All data underwent
177 a normality test (Shapiro–Wilk), and were found to be non-normally distributed. As a result, all
178 circRNA data underwent a logarithmic transformation (with base 2), in order to better approximate
179 the normal distribution. The parametric t-test was used to observe differences between healthy

180 controls and PD patients. We applied the Benjamini – Hochberg false discovery rate correction in
181 the resulting p-values to account for the multiple number of tests. Spearman’s method with
182 Bonferroni correction for multiple comparisons was used to correlate circRNA expression levels
183 with participants’ demographic and clinical characteristics (p-value threshold 0.0005).

184 To assess the possibility that sex is a confounding factor, the two-way ANOVA model was applied
185 to the log-transformed data (normally distributed) with sex as an additional factor. No difference
186 in the circRNAs that were statistically significant was found.

187 Receiver operating characteristic (ROC) curves were constructed and the area under the curve
188 (AUC) was calculated to evaluate the predictive sensitivity and specificity of PBMC circRNAs for
189 PD diagnosis. The cutoff value for the ROC analysis was determined using the Youden Index.

190 Data are presented as means \pm SEM. circRNA selection was based on the stepwise removal
191 approach. A logistic regression statistical model containing all available circRNAs as independent
192 variables and PD status as the dependent variable was built. Then, the circRNAs with the least
193 contribution in the model (as determined by an F test) were removed. This process continued until
194 no further removals were possible.

195

196 **Data availability**

197 The datasets analysed during the current study are all available from the corresponding author on
198 request.

199

200 **RESULTS**

201 **circRNAs are differentially expressed in PBMCs of idiopathic PD patients**

202 The demographic and clinical characteristics of 60 healthy controls and 60 iPD patients are
203 summarized in Table 1. The mean age of 64.5 and the sex ratio were the same for both groups.
204 The disease duration for the PD group was 4.8 ± 0.55 years and the MMSE score 27.5 ± 0.56 .
205 Initially, RT-qPCR was employed to detect plasma levels of 32 circRNAs that are highly-
206 expressed by brain cells. It was anticipated that a sufficient quantity of brain-derived circRNAs
207 would find its way into the plasma. However, only two circRNAs, RMST (at Ct 29) and PSD3 (at
208 Ct 28), were detected. Using the same amount of RNA, this time extracted from human brain
209 tissue, it was revealed that all circRNAs were readily detectable with an average Ct value of 26,
210 demonstrating that all primer pairs were functional (data not shown). This indicated that brain-
211 enriched circRNAs are not as abundant as brain-enriched miRNAs (average Ct value of 17.5 for
212 21 brain-enriched miRNAs in the same human brain total RNA) and are not circulating in
213 appreciable amount in the blood (average Ct value for the corresponding miRNAs in the plasma
214 is 25)⁴³.

215 Based on previous studies showing that genome-wide transcriptional and alternative splicing
216 profiles in peripheral blood cells parallel changes in gene expression in the brain, the levels of
217 circRNAs were next assessed in PBMCs. We increased the number of primer sets to 87 and found
218 that 48 were detected with a Ct value below 30, safeguarding accurate and reproducible detection.
219 These circRNAs were then analyzed for differential expression in healthy control and iPD patient
220 samples (Suppl. Table 3).

221 Following multiple comparison adjustment, six circRNAs were significantly altered in the PBMCs
222 obtained from PD patients compared to healthy controls. MAPK9_circ_0001566,
223 HOMER1_circ_0006916, SLAIN1_circ_0000497, DOP1B_circ_0001187,
224 RESP1_circ_0004368, and PSEN1_circ_0003848 were all downregulated in the PD cohort (Fig.

225 2 and Suppl. Table 3). The swarm plots for the 42 circRNAs whose relative expression was not
226 significantly altered in the PBMCs of idiopathic PD patients are shown in Supplemental Fig 1.

227

228 **Association between circRNA levels and clinical features, age or sex**

229 Spearman correlation test was used to relate circRNA levels to iPD patients' clinical features. We
230 found no correlation between age-at-onset, disease duration, UPDRS III, MMSE, LEDD, H&Y or
231 patients' on/off state and circRNA levels (Suppl. Table 4 and data not shown). Finally, correcting
232 clinical scores with LEDD did not reveal any more associations (data not shown). In addition,
233 there was no significant correlation between circRNA expression and age or sex in either healthy
234 controls or PD patients.

235

236 **Discriminant Analysis**

237 To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy
238 controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four
239 circRNA panel (SLAIN1_circ_0000497, SLAIN2_circ_0126525, ANKRD12_circ_0000826, and
240 PSEN1_circ_0003848) were 75.3% (62.1-85.2%) and 78% (65.8-88%), respectively, and the AUC
241 was 0.84 (Fig. 3).

242

243 **CeRNA networks**

244 CircRNAs can act as miRNA and RBP sponges for regulating gene expression. To explore the
245 functional role of the deregulated circRNAs we identified all their miRNA and RBP targets.
246 Multiple miRNA binding sites are predicted for each circRNA, with SLAIN1_circ_0000497 and
247 MAPK9_circ_0001566 having the most of MREs (38 and 24, respectively) (Fig. 4A).

248 Interestingly, five miRNAs were predicted to be sponged by half or more of the deregulated PD
249 circRNAs. miR-526b and miR-659 are the top targets, sequestered by four deregulated PD
250 circRNAs (Fig. 4A). Fig. 4B shows the deregulated circRNA-RBP network. Like for miRNAs,
251 CLIP-Seq data obtained from StarBase database revealed that the deregulated circRNAs have
252 multiple RBP binding sites. MAPK9_circ_0001566 and HOMER1_circ_0006916 host the most
253 of these sites with 60 and 49 sites, respectively. Interestingly, 29 RBPs were sequestered by four
254 or more deregulated circRNAs.

255

256 **CircRNA-miRNA pathway analysis**

257 In order to explore the biological pathways affected by the five miRNAs (miR-516b-5p, miR-
258 526b-5p, miR-578, miR-659-3p, and miR-1197) mostly sequestered by three or more of the
259 deregulated circRNAs, the DIANA mirPath v3 tool was used to align miRNA predicted targets
260 with KEGG pathways and GOslim categories. A Priori gene union analysis of deregulated miRNA
261 targets revealed fourteen KEGG categories as significantly enriched; they included ‘Thyroid
262 hormone signaling pathway’ ($p < 0.0015$, 24 genes), ‘Regulation of actin cytoskeleton’ ($p < 0.015$,
263 42 genes) ‘Phosphatidylinositol signaling pathway’ ($p < 0.016$, 16 genes), ‘MAPK signaling
264 pathway’ ($p < 0.016$, 46 genes) and ‘FoxO signaling pathway’ ($p < 0.016$, 26 genes) (Suppl. Table
265 5A). Similar findings were obtained using a Posteriori analysis (Suppl. Fig. 2A). Thirty-nine
266 GOslim categories that are controlled by the gene union of the deregulated miRNA targets were
267 enriched following a Priori analysis; these included ‘Cellular protein modification’ ($p < 3.93E-19$,
268 283 genes), ‘Nucleic acid binding transcription factor activity’ ($p < 7.74E-07$, 112 genes),
269 ‘Cytoskeletal protein binding’ ($p < 3.91E-09$, 102 genes) ‘Cell death’ ($p < 7.91E-08$, 112 genes),

270 ‘RNA binding’ ($p < 6.93E-07$, 207 genes) and ‘Response to stress’ ($p < 3.72E-05$, 225 genes)
271 (Suppl. Table 5B). Similar findings were obtained using a Posteriori analysis (Suppl. Fig. 2B).

272

273 **DISCUSSION**

274 We profiled brain-enriched circRNAs in peripheral blood from controls and patients with PD using
275 a RT-qPCR -based approach for three reasons. First, primers could be designed to span the splicing
276 junction which guarantees that only message from the circRNA is amplified. Second, RT-qPCR is
277 the most sensitive method to accurately determine expression changes between cohorts; the
278 alternative microarray approach is prone to errors at multiple levels and nearly always requires a
279 follow up RT-qPCR-based analysis to validate findings. Third, we probed circRNAs that are
280 abundantly expressed in the brain; in this way, we could identify differentially expressed or spliced
281 circRNAs that are more likely associated with the neurological processes of PD.

282 **Insights into the differentially expressed circRNA genes**

283 We initiated our study with 87 brain-enriched circRNAs from which over half were confidently
284 detected in PBMCs. From these circRNAs, six were differentially expressed in PD with a 17%
285 decrease on average from healthy controls levels. These changes may appear subtle but depending
286 on the circRNA baseline expression levels and considering the relative importance of their multiple
287 targets (transcription factors, RBPs, and miRNAs) as well as the added-up deregulation of the
288 common targets, the biological outcome is expected to be significant.

289 It has been observed that the biological role of host transcripts reflects on the function of the
290 circRNAs¹⁷. We found that the host transcripts of the differentially-expressed circRNAs are not
291 exclusive to brain pathways; rather, they are house-keeping genes, whose functions are best

292 characterized in the CNS as they are essential for neuronal homeostasis. A brief bibliographical
293 overview of their properties is described below.

294 Hsa_circ_0001566 is hosted by the mitogen-activated protein kinase 9 (MAPK9) gene.
295 MAPK9/JNK2 is a member of the c-Jun n-terminal kinase 1-3 family robustly activated by
296 environmental stresses, including the PD-related neurotoxins lipopolysaccharides (LPS), MPTP
297 and 6-hydroxydopamine (6-OHDA) to mediate neuronal degeneration ⁴⁴. It is indispensable during
298 brain development for neuronal migration, axonal sprouting and guidance, as well as neuronal
299 survival ⁴⁵. Hsa_circ_0006916 is hosted by the homer scaffold protein 1 (HOMER1) gene.
300 HOMER1 is a member of Homer 1-3 family constituting important scaffold proteins at the
301 postsynaptic density that associate with a large number of Ca²⁺-handling proteins, including
302 channels, receptors, and shank scaffolding proteins to regulate intracellular Ca²⁺ homeostasis ⁴⁶.
303 An SNP in the promoter of HOMER1 has been associated with psychotic symptoms in PD ⁴⁷.
304 Further, circHomer1a is reduced in the prefrontal cortex of patients with schizophrenia and bipolar
305 disorder, where it modulates the alternative splicing of mRNA transcripts involved in synaptic
306 plasticity and psychiatric disease ¹¹. Hsa_circ_0000497 is hosted by the SLAIN motif family
307 member 1 (SLAIN1) gene. SLAIN1 and 2 are microtubule-associated proteins that promote
308 persistent microtubule growth by recruiting the microtubule polymerase ch-TOG to microtubule
309 plus-ends and thus they are important for axon elongation in developing neurons ⁴⁸. Recently,
310 SLAIN1 was identified as a candidate gene for intellectual disability ⁴⁹. Hsa_circ_0001187 is
311 hosted by the DOP1 leucine zipper like protein B (DOP1B) gene. DOP1B/ DOPEY2/ C21orf5 and
312 its ortholog DOP1A interact with partner MON2 to retrograde transport endosomes from the TGN
313 to the Golgi ^{50, 51}. DOP1B is a candidate gene for mental retardation in Down syndrome ^{52, 53} and
314 copy number variations (CNVs) have been observed in AD ^{54, 55}. Hsa_circ_0004368 is hosted by

315 the RALBP1 associated eps domain containing 1 (REPS1) gene. REPS1 is a signaling and
316 endocytosis adaptor that interacts with adaptor Intersectin 1 (ITSN1) in clathrin-coated pits and
317 Amphiphysin 1 (AMPH) at the surface of synaptic vesicles⁵⁶. Mutations in REPS1 are associated
318 with neurodegeneration with brain iron accumulation (NBIA) in the basal ganglia⁵⁷.
319 Hsa_circ_0003848 is hosted by the presenilin 1 (PSEN1) gene. PSEN1 and its paralog PSEN2 are
320 the endoprotease subunits of the gamma-secretase complex that catalyses the intramembrane
321 cleavage of integral membrane proteins such as Notch receptors and amyloid-beta precursor
322 protein (APP). Mutations in either gene cause early-onset AD⁵⁸ and α -synuclein accumulation in
323 LB in these patients⁵⁹. Besides their established role in mediating the formation of A β peptide,
324 more recently mutant PS1 has been shown to impair numerous cellular functions such as calcium
325 flux, organization of proteins in different compartments, and protein turnover via vacuolar
326 metabolism⁶⁰. Interestingly, a novel PSEN1 mutation was recently identified as the likely cause
327 for early-onset Parkinsonism⁶¹.

328 **Correlation between circRNA levels and demographics**

329 There was no significant correlation between the differential expression of a particular circRNA
330 and clinical or demographic measures. Combined interactions with age and sex did not also appear
331 to affect circRNA levels. These findings reinforce current knowledge that the etiology of PD is
332 complex involving a mix of genetic and environmental influences on ageing brain. Similar findings
333 have been observed in miRNA studies⁶². Further, a pool of four circRNAs discriminated subject
334 with PD from controls with an AUC of 0.84.

335 **CircRNA-RBP and circRNA-miR interactions**

336 *In silico* approaches were utilized to identify potential biological roles for the deregulated
337 circRNAs by identifying the RBPs and miRNAs that are sequestered preferentially by them. Since

338 the circRNAs were all downregulated, it indicates that target RBP and miRNA functions will be
339 enhanced in PD. The circRNA-RBP network which is based on experimental CLIPS-seq data
340 revealed that 29 RBPs were bound by four or more deregulated circRNAs. Importantly, several of
341 these RBPs are implicated in familial neurodegeneration including Fragile X Mental Retardation
342 Protein 1 (FMR1, Fragile X syndrome and associated disorders), Ataxin 2 (ATXN2,
343 Spinocerebellar ataxia 2, late-onset PD), Fused in Sarcoma (FUS) and TAR DNA binding protein
344 (TARDBP/TDP43) (Amyotrophic lateral sclerosis, Frontotemporal dementia) ⁶³⁻⁷².
345 The circRNA-miRNA network revealed five miRNAs that were predicted to be sponged by at least
346 three downregulated PD circRNAs. miR-659-3p is of particular interest as it targets progranulin
347 (PGRN), a neuroprotective and anti-inflammatory protein implicated in FTD ⁷³⁻⁷⁷. To explore the
348 molecular pathways controlled by the five miRNAs, *in silico* analysis of KEGG pathways and
349 GOslim terms was performed. KEGG categories revealed multiple signaling pathways (Thyroid
350 hormone, Phosphatidylinositol, MAPK, FoxO) implicated in neuronal survival and plasticity and
351 ‘Regulation of actin cytoskeleton’ which is central to pre- and postsynaptic assembly as over-
352 represented ⁷⁸⁻⁸¹. GOslim analysis revealed ‘Cellular protein modification’, ‘Nucleic acid binding
353 transcription factor activity’, ‘Cytoskeletal protein binding’, ‘Cell death’, and ‘Response to stress’
354 as overrepresented among the biological processes affected. ‘Cellular protein modifications’ such
355 as phosphorylation, ubiquitination, truncation, acetylation, nitration and sumoylation of PD-linked
356 proteins have emerged as important modulators of pathogenic mechanisms in PD ^{82, 83}.
357 ‘Transcription factor’ changes indicate that there is not only misexpression at the mRNA
358 translation level by miRNA deregulation, but that there exists a second wave of *en masse*
359 deregulation involving transcription-mediated changes. Finally, deregulation of fine cytoskeletal
360 dynamics is expected to impair trafficking and intracellular signaling pathways and has been

361 recognized as a key insult in the pathogenesis of multiple neurodegenerative diseases including
362 PD^{84, 85}.

363 **Conclusions**

364 We performed an RT-qPCR-based analysis on RNA extracted from PBMC cells from a cohort of
365 patients with PD and matched controls to identify deregulated circRNAs. The circRNAs
366 investigated are highly-expressed in the human brain. This is the first study of its kind in PD. The
367 measurement of four out of six downregulated circRNAs provided reasonable sensitivity and
368 specificity for PD in this discovery cohort. The circRNAs found deregulated form a robust set of
369 brain-associated circRNAs, that can now be further evaluated, along with other measures, as
370 diagnostic and possible therapeutic targets for PD. *In silico* analysis provided a comprehensive
371 guide of the pathways and processes they control, shedding light on their potential biological role.
372 The impact of these findings will now await further exploration.

373

374 **ABBREVIATIONS**

375 6-OHDA, 6-hydroxydopamine; ANCOVA, analysis of covariance; ANOVA, analysis of variance;
376 APP, amyloid-beta precursor protein; AUC, area under the curve; circRNA, circular RNA; CT,
377 computed tomography; DOP1B, DOP1 leucine zipper like protein; FTD, Frontotemporal
378 dementia; GO, gene ontology; H&Y, Hoehn & Yahr; HC, healthy control; HDAC, histone
379 deacetylase; HOMER1, homer scaffold protein 1; hsa, homo sapiens; iPD, idiopathic PD; KEGG,
380 Kyoto encyclopedia of genes and genomes; LEDD, Levodopa equivalent daily dose; LPS,
381 lipopolysaccharides; MAPK9, mitogen-activated protein kinase 9; MMSE, Mini Mental State
382 Examination; MRI, magnetic resonance imaging; NBIA, neurodegeneration with brain iron
383 accumulation; PD, Parkinson's disease; PSEN1, presenilin 1; REPS1, RALBP1 associated eps

384 domain containing 1; SNCA, alpha-synuclein; SLAIN1, SLAIN motif family member; UPDRS,
385 unified Parkinson's disease rating scale; TARDBP, TAR DNA Binding Protein; UTR,
386 untranslated region.

387

388 **ACKNOWLEDGMENTS**

389 The authors are grateful to patients, relatives, and volunteer healthy controls for their participation
390 in this study. This research was financed by Greece and European Union (European Social Fund-
391 ESF) through the Operational Program «Human Resources Development, Education and Lifelong
392 Learning 2014-2020» in the context of the project “Development of diagnostic biomarker tests for
393 Parkinson's disease” (MIS 5049385). It was also co-financed by the action “Precision medicine
394 Hellenic network in genetic neurodegenerative diseases” (2018ΣΕ01300001) of the Hellenic
395 public investments program of GSRT and the Michael J. Fox Foundation for Parkinson's Research
396 (Grant ID 13353).

397

398 **AUTHORS' ROLES**

399 Conceived the study: ED. Neurologically examined patients: AB, NP, LS. Peripheral blood
400 processing: MM. Differential expression analysis: SR, DK, ED. Analyzed data: SR, NP, ED.
401 Bioinformatics analyses: ED. Wrote the manuscript: ED. All authors read, edited and approved
402 the final manuscript.

403

404 **FINANCIAL DISCLOSURES**

405 **Stylianos Ravanidis:** SR is a postdoctoral researcher at BRFAA. No Disclosures.

406 **Anastasia Bougea:** AB is a neurology resident at Eginition Hospital. No Disclosures.

407 **Dimitra Karampatsi:** DK is a former MSc student at BRFAA. No Disclosures.

408 **Nikolaos Papagiannakis:** NP is a neurology resident at Eginition Hospital. No Disclosures.


409 **Matina Maniati:** MM is a technician at BRFAA. No Disclosures.

410 **Leonidas Stefanis:** Leonidas Stefanis is employed by the National and Kapodistrian University
411 of Athens and the Biomedical Research Foundation of the Academy of Athens. He has the
412 following active grants: Fondation Sante research grant, a Michael J. Fox Foundation grant as a
413 collaborator and an ELIDEK grant. He has served on an Advisory Board for Abbvie, Novartis and
414 Roche and has received honoraria from Abbvie and Sanofi.

415 **Epaminondas Doxakis:** ED is employed by BRFAA. He has one active MJFF research grant.


416

417 FIGURES



418


419 **Figure 1. Schematic representation of the workflow.**



420


421 **Figure 2. Swarm plots of deregulated circRNAs relative expression in the PBMCs of control**
 422 **and idiopathic PD cohorts.** Mean levels +/- SEM are included below each graph. Graphs
 423 demonstrate relative expression of log-transformed data. Unpaired t-test was used to determine the
 424 significance of differences between the two groups. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

425



426

427 **Figure 3. The receiver operating characteristic (ROC) curve analysis for discriminating**
 428 **idiopathic PD from healthy control subjects.** ROC curve of four circRNAs
 429 (MAPK9_circ_0001566, SLAIN1_circ_0000497, SLAIN2_circ_0126525, and
 430 PSEN1_circ_0003848) differentiate iPD from HC cases.




431

432 **Figure 4. CircRNA target networks.** Diagrams show (A) the predicted miRNAs and (B) the
 433 CLIP-Seq identified RBPs that bind to differentially expressed circRNAs.



434

435


436 SUPPLEMENTAL FIGURES




437



438




439



440

441 **Supplemental Figure 1. Swarm plots for the 42 circRNAs whose relative expression is not**
 442 **significantly altered in the PBMCs of idiopathic PD patients. Mean levels +/- SEM are included**
 443 **below each graph. Graphs demonstrate relative expression of log-transformed data. Unpaired t-**
 444 **test was used to determine the significance of differences between the two groups. *p<0.05,**
 445 ****p<0.01, ***p<0.001.**

446



447

448 **Supplemental Figure 2. KEGG and GOslim classifications of the circRNA-miRNA target**

449 **genes. (A) KEGG and (B) GOslim categories union of the RNA targets of the five miRNAs**

450 **sequestered by three or more of the deregulated PD circRNAs (miR-516b-5p, miR-526b-5p, miR-**

451 **578, miR-659-3p, miR-1197). They were prepared using the DIANA-miRPath v3.0 interface using**

452 **default values (p-value threshold 0.05, microT-CDS threshold 0.8).**

453

454

455 **TABLES**

456

457 **Table 1. Demographic and clinical profiles of healthy controls and PD patients.**

<i>Variables</i>	Healthy controls	iPD	<i>P</i> value
No of subjects	60	60	N/A
Age^a	64.38 ± 1.335	64.73 ± 1.33	0.84
Sex (M/F)	29/31	29/31	1
Age of onset^a	N/A	59.95 ± 10.97	N/A
Disease duration^{a, b}	N/A	4.78 ± 0.55	N/A
UPDRS III^{a, c}	N/A	25.77 ± 1.92	N/A
(on/off state)		(42/18)	
MMSE^{a, d}	N/A	27.53 ± 0.56	N/A
H&Y^{a, e}	N/A	1.82 ± 0.10	N/A
LEDD^{a, f}	N/A	496.9 ± 59.71	N/A

458

459 ^a ± SD.

460 ^b Disease duration is counted in years.

461 ^c Unified Parkinson's Disease Rating Scale.

462 ^d Mini Mental State Examination.

463 ^e Hoehn & Yahr.

464 ^f Levodopa equivalent daily dose.

465

466

467 **SUPPLEMENTAL TABLES**

468

469 **Supplemental Table 1. Primer sequences used for real-time PCR.**

circRNA	Forward	Reverse
hsa_AFF2_circ_0001947	ACTGCCAAAGTTCACCATCC	AGTTTCCAAGCGTGTCTGG
hsa_AGTPBP1_circ_0007162	GTGGATTCGTATGGGGACTG	CCTGCCGTAGGAACAACAAT
hsa_ANKRD12_circ_0000826	CGTCCAGTGGATGTAGCAGA	AACCCAGATTTGGGCATTTT
hsa_ANKS1B_circ_0007294	TGGGAAAATGGAAGCCAGAGT	AGAACTCGTACAACATCCACCT
hsa_ARPP21_circ_0001281	GTCCATCGAGTGGCAGCTT	ATGCCCATCTCCATGCGATT
hsa_ATP6V0A1_circ_0043837	CGCCGTCAGTATTTGAGGAG	GGCTGACTCCAAACAGCATA
hsa_BACH1_circ_0001181	CGCTGTGCAAGAGAAAAC	AGGCAAAAACCGAGTTCTCA
hsa_CDR1_circ_0001946	CATGTCTTCCAACGTCTCCA	ACCTTGACACAGGTGCCATC
hsa_CNTNAP2_circ_0133631	GGATGCTCTACAGCGACACA	GGGAGTCCAGAGACAAGTGG
hsa_CORO1C_circ_0000437	ATGGGTTACATGCCAAGAG	ACACCCCATTGCTAGTGTCC
hsa_CSNK1G3_circ_0001522	GCACCACAGCTACATTTGGA	GCATGTTTATCCCATTCGT
hsa_DAB1_circ_0113684	TGTGCCAAAAAGTCAACCTG	CCCGGTGATCTGTAATGTCC
hsa_DGKB_circ_0133622	AGGAGACCCAGTGCCTTACA	GGTCCTTCAAAGGTCCACAG
hsa_DNAJC6_circ_0002454	TGACATTCGAAGCTTTTTGG	ATAGCTGGGCTCCATGTCTG
hsa_DOP1B_circ_0001187	GGAATGTTCTCAGAAAGGAGGA	AATGTTTTCCCTCTTGAGGT
hsa_ERC2_circ_0124264	CGGATTGAGAGGAGGAAACA	TTGATTGTGCTTGAGGTTGG
hsa_EXOC6B_circ_0009043	TCCGCAAACATTCAGACAAA	GCTTCAGCTCTTCCATTGCT
hsa_EXOSC1_circ_0005887	CCCGAATTCCTTGACAGACCTA	ACCTGGGCGGAAACTCTTAT
hsa_FAM120A_circ_0001875	TGTCATTTTCATCCACCACATT	CAAGCCATGGAAACCATTCT
hsa_FGD4_circ_0000390	TAGCTGCTCGGAACACTTCA	GCATGTGATGCTGCAAAGTT
hsa_FKBP3_circ_0101874	AAGGCTCGACTGGAGATTGA	GCTGTCTTGCCACATTTTTT
hsa_FUT8_circ_0003028	GTCCAAGATTCTGGCAAAGC	TCAAAGAGATCCTCCTGGTGA
hsa_GBAS_circ_0001709	GAATGAGCCTGTGCCAAGAT	TTCTGTGAGGGCTGGATAGC

hsa_GRIN2B_circ_0097968	CTGAGCCCAAAGCAGTTGT	TTACGGAAGCTTGCTGTTCA
hsa_HAGH_circ_0105101	CAGGGAGAAGGACCAGTTCA	GCTCCCCGATGCTGTACTT
hsa_HAT1_circ_0008032	TGCTGGTAGCCTGTCAACAA	GCCAGTTTCTTCTCCACTGC
hsa_HIPK3_circ_0000284	TCGGCCAGTCATGTATCAAA	GGGTAGACCAAGACTTGTGAGG
hsa_HMGCLL1_circ_0131944	CAGGTGCTCTTGCTGTTTAC	CATCCCTAGGCCCAACTTCT
hsa_HOMER1_circ_0006916	AATGCATTGCCATTTTCACA	TGTGTTTGGGTCAATTTGGA
hsa_HTTP_circ_0001392	TTTGGCAATTTTGCAAATGA	CACACGGTCTTCTTGGTAGC
hsa_KCNN2_circ_0127664	CCGAGCTTGTGAAAGTTGTTT	CACACACCAGTATTTCCAAGCA
hsa_KDM4C_circ_0001839	ATGGCTACCATGCTGGTTTT	TCAAGTCGTTTTCCATGCTC
hsa_KIAA1841_circ_0007793	GGACCGAGTCAAGTCAAAGG	TGGGCACAGGGTGAAGATAC
hsa_KIDINS220_circ_0005315	ACCGGACTTCATGGCTCATA	CCTCTGCATCTGCCTTCTTC
hsa_KLHL1_circ_0100796	GGAATTCGAGCCTTCGCAGA	TGGAGTCCAAATCACTTTGAGGT
hsa_LMBR1_circ_0005939	GGCTAAATGGCTCCCTGATT	CGATGGCATCTTCATCTTCTT
hsa_LPAR1_circ_0087960	GGCTGCCATCTCTACTTCCA	GTGGATGGGGAGCTTCATAA
hsa_LRCH1_circ_0002215	GGAAGCATGCCGAAAATTAG	TCCTCCGGATTGTAAACTGC
hsa_LRCH3_circ_0002266	TCCCAAATTGGTAACCTGGA	CCAGAGAAACAAAGTGACATGCT
hsa_LRRC7_circ_0114013	TGGACAAGGAAATCCATTCA	TCCATTGGCCACTAGGAGAT
hsa_MAPK8_circ_0002968	TGTGGAATCAAGCACCTTCA	AAAATTGTTGTCACGCTTGC
hsa_MAPK9_circ_0001566	TGGAGCTGGATCATGAAAGA	AAGGGTGGGCAAGTTTCAG
hsa_MED12L_circ_0067735	CAACGTGGCTGATCAAGATG	GGCTGGCTGATTATTGAAGC
hsa_NRXN1_circ_0054525	TTCCAGGGTCACCAGTCAGT	GATCCTTTGAACGTGGCAAT
hsa_NTRK2_circ_0139142	CCTGAATGAAAGCAGCAAGA	ACCTTTTCTGGTTTGCGATG
hsa_PAK3_circ_0139566	GTTGGGGACCCAAAGAAAAA	ATCAAACCCACATGAATCG
hsa_PDE4B_circ_0008433	ACTGCCTTTGACAACGCTTC	TTCAATGCAGTTTGCTGACA
hsa_PHC3_circ_0001359	TGTCACCCGGACATCAAGTA	GGTAATACTGCCGCTGGTA
hsa_POMT1_circ_0001897	CTGGCCTTTGGGAGGTTATTT	GCCCACTGTCATCCAAGAAG
hsa_PPP2R2B_circ_0128256	GCGTGATAAGAGGCCAGAAG	AATTCTCCCGTGTGGTTGAA

hsa_PRKCB_circ_0000682	ACAGGGACGTCTCATTGTC	GTCACATTTTCATCCCCTGGT
hsa_PSD3_circ_0002111	TGCAAGGGGTAAATGAGGGTG	TTCAGTGCTCCCCATTTTCAGA
hsa_PSEN1_circ_0003848	AGTTACCTGCACCGTTGTCC	GCTGTCTAAGGACCGCAAAG
hsa_PTK2_circ_0003171	GATGGCTCCAGAGTCAATCAA	CTCACGCTGTCCGAAGTACA
hsa_R3HDM1_circ_0001070	AAGGATCTATGCCACAACAGG	GACTCTGGGGTTGCTGAACT
hsa_REPS1_circ_0004368	CCATTCAGCCTGATCTAAACG	ACACTGCATCACCAGCAGAA
hsa_RERE_circ_0002158	TAAAGCCCGAGTGGATTCAT	TGACGTTTCATGAGGAGATGG
hsa_RIMS1_circ_0132246	GGAGATCCAGCCTTAGTGCC	AGCTTGCTTTTGTGGAAGAGT
hsa_RIMS1_circ_0132250	AGCAGGTGGAAAGAAACGGA	TGCTTGTTTCGCTCCTCCAC
hsa_RIMS2_circ_0005114	TCTGTACGGAAAAGTCGCA	TGATCCGGCTACCTGTTTGT
hsa_RMST_circ_0099634	AGGGGCTAGTTGAGGAATGG	CCATTCTGTGCTGAGTGGAG
hsa_RTN4_circ_0054598	GAGGACAGATCACCATCTGCTA	TGCAGAGGAGCGTATCACAG
hsa_SCAF8_circ_0001654	CTTGCGGCTGTAGCTCAGAT	TTTGGGTCATTTTCGCTTTC
hsa_SCLT1_circ_0001439	GAACATGGAAGTACTAACCAACA	GGGAAAGGCCTCCAATTTT
hsa_SFMBT2_circ_0000211	ATGGCCTCTGAATGGAAATG	CTCGAACCAGTCAAGTCACG
hsa_SLAIN1_circ_0000497	GCTTGCATGGAGCTGGAAATG	ATGTCTACACCACTGCAAAGGA
hsa_SLAIN2_circ_0126525	AAGTGCCAAACGGAGGAATA	AATCCAAAACCTGCCTGCAC
hsa_SLC30A6_circ_0005695	CCGTGCCTGAGCAATAGTTT	TGCACCACATAAGCAGGAAG
hsa_SLC38A1_circ_0000396	CATTATGGGCAGTGGGATTT	GTATGGCCTTCCAGGGTTTT
hsa_SMARCA5_circ_0001445	TGGGCGAAAGTTCACTTAGAA	GAAGCATTTCATCTTTCCAAT
hsa_STX6_circ_0007905	GGCTGGACAATGTGATGAAG	GCCTGCACAGATGAAGTTGA
hsa_SYT1_circ_0099287	ACAGTGGATTTTGGCCATGT	AAAAGCAGCAGGTCAGGACT
hsa_TMCC1_circ_0001340	GGGAAGCTATTGCTGGGATT	ACCAAAGGCAACTGTTCCACC
hsa_TMEFF1_circ_0004425	GGTCAGGGGCAGAAGTTCAC	CTCTTACGTCAGACTCCCTCAC
hsa_TMEM132D_circ_0097876	CAAAGACCGTGAGGAAAGGA	GCAAGGAAAACCTCTGGATG
hsa_TMEM138_circ_0002058	GCTGGAAAACTCCAACAGC	AGCCTGGAAGACGAAGGTGT
hsa_UBE2K_circ_0002590	CAGAGCCAGATGATCCACAG	GTGTGTCTGGAGGTCCTGCT

hsa_UBXN7_circ_0001380	TGCATAAAGGCAGCTTTGAA	CCGTCGTCTTTTAGGAGCAC
hsa_UIMC1_circ_0001558	CCCACAAAGATTGAACGACA	GCAGCAACACTTTGTGAAGC
hsa_UNC13C_circ_0103896	AAAGCAAATGGCAGAGTTGG	AAACCAGAAGCAAAGCTCCA
hsa_VMP1_circ_0006508	TCTTCTGTTGGGCTTGGAAC	TTCCATTCTCTGCCATTCA
hsa_VPS13C_circ_0000607	AAGCACAGGCAGTTACTCAAGA	GCATGGAGTCCAGTGTTTCATT
hsa_WDR78_circ_0006677	GAAGACCTGGAAGAACCATCC	TCTGCTTTGATTTGCACCAG
hsa_YY1AP1_circ_0014606	ATTCTGGACCCAGCACAAAG	TCTTCTGGGCCATCATCTTC
hsa_ZFAND6_circ_0000643	TGTGGACAAAGCAGTACCTGA	CCATTTGTACGAGGGTTTCC
hsa_ZMYM4_circ_0011536	GCACCACAGCAGGGACTACT	ATCCTGTTTGATTTCGGCATT
hsa_ZNF292_circ_0004058	TTCTTTCCCAGGAACCATTG	CGGGCTTTAACATAACTTTGG
hsa-GAPDH	GCACCACCAACTGCTTAG	GCCATCCACAGTCTTCTG
hsa-U6	CGCTTCGGCAGCACATATAC	TTCACGAATTTGCGTGTCAT

470

471 **Supplemental Table 2.** List of 39 circRNAs not detected in PBMCs

ANKS1B_circ_0007294	KLHL1_circ_0100796	RERE_circ_0002158
ARPP21_circ_0001281	LMBR1_circ_0005939	RIMS1_circ_0132246
CDR1_circ_0001946	LPAR1_circ_0087960	RIMS1_circ_0132250
CNTNAP2_circ_0133631	LRCH1_circ_0002215	<u>RIMS2_circ_0005114</u>
DAB1_circ_0113684	LRR7_circ_0114013	RMST_circ_0099634
DGKB_circ_0133622	NRXN1_circ_0054525	SCAF8_circ_0001654
ERC2_circ_0124264	NTRK2_circ_0139142	SLC30A6_circ_0005695
EXOSC1_circ_0005887	PAK3_circ_0139566	STX6_circ_0007905
FGD4_circ_0000390	PDE4B_circ_0008433	SYT1_circ_0099287
GRIN2B_circ_0097968	PPP2R2B_circ_0128256	TMEFF1_circ_0004425
HAGH_circ_0105101	PRKCB_circ_0000682	TMEM132D_circ_0097876
HMGCLL1_circ_0131944	PSD3_circ_0002111	UNC13C_circ_0103896
KCNN2_circ_0127664	PTK2_circ_0003171	YY1AP1_circ_0014606

472

473 **Supplemental Table 3. Basic characteristics and comparative PBMC circRNA expression in**

474 **idiopathic PD patients and healthy controls.**

475 CircRNA size and expression in the brain as well as host transcript expression in the body. Means

476 with their respective standard deviation (std) for both groups are shown. Statistically significant

477 differences in comparison to healthy controls (unpaired t-test) are highlighted in grey. Multiple

478 comparison analysis (adjusted *P* values) calculated according to Benjamini-Hochberg false

479 discovery rate method.

480

circRNA ID	Spliced Seq length	Expression score in the human brain*	Host gene symbol	Host gene mRNA expression in the human body**	Mean (± std)		Unpaired t-test <i>P</i> value	Adjusted <i>P</i> values
					HC	iPD		
circ_0001380	247	15326	UBXN7	Ubiquitous, expressed least in the brain except cerebellum where expression is similar to other tissues	-0.046 (0.348)	-0.016 (0.432)	0.678	0.812
circ_0000284	1099	13889	HIPK3	Ubiquitous, expressed least in the brain	-0.073 (0.443)	-0.165 (0.435)	0.252	0.603
circ_0001445	269	9354	SMARCA5	Ubiquitous, lower expression in the brain	-0.132 (0.565)	-0.275 (0.504)	0.147	0.415
circ_0009043	390	9121	EXOC6B	Ubiquitous, enriched in the skin	-0.061 (0.395)	-0.089 (0.425)	0.701	0.812
circ_0001947	861	9058	AFF2	Ubiquitous, highly enriched in the cerebellum	-0.208 (0.702)	-0.302 (0.531)	0.412	0.706
circ_0002590	336	8841	UBE2K	Ubiquitous, enriched in the cerebellum	-0.062 (0.409)	-0.073 (0.437)	0.895	0.895
circ_0000437	251	8402	CORO1C	Ubiquitous, expressed least in the brain	-0.224 (0.736)	0.007 (0.911)	0.130	0.390
circ_0000497	788	6004	SLAIN1	Brain-specific	-0.096 (0.520)	-0.447 (0.313)	<0.0001 ***	0.001***
circ_0054598	2457	5985	RTN4	Ubiquitous, enriched in the brain	-0.165 (0.624)	-0.139 (0.583)	0.815	0.850
circ_0001522	536	5649	CSNK1G3	Ubiquitous, lower expression in the brain	-0.077 (0.452)	-0.190 (0.505)	0.205	0.518
circ_0001070	307	5300	R3HDM1	Brain-specific	-0.058 (0.394)	0.050 (0.523)	0.204	0.518
circ_0011536	755	4662	ZMYM4	Ubiquitous, expressed least in the brain except	-0.064 (0.417)	-0.093 (0.406)	0.694	0.812

				cerebellum where expression is somewhat higher than in other tissues				
circ_0000607	606	4056	VPS13C	Ubiquitous, expressed least in the brain except cerebellum where expression is similar to other tissues	-0.078 (0.449)	0.021 (0.514)	0.266	0.603
circ_0001439	396	3870	SCLT1	Ubiquitous, expressed least in the brain except cerebellum where expression is somewhat higher than in other tissues	-0.056 (0.399)	-0.209 (0.429)	0.046*	0.210
circ_0000826	994	3868	ANKRD12	Ubiquitous, expressed least in the brain except cerebellum where expression is somewhat higher than in other tissues	-0.059 (0.405)	-0.217 (0.355)	0.024*	0.142
circ_0000211	434	3783	SFMBT2	Ubiquitous	-0.076 (0.457)	-0.239 (0.381)	0.036*	0.189
circ_0002266	378	3204	LRCH3	Ubiquitous, expressed least in the brain except cerebellum where expression is somewhat higher than in other tissues	-0.089 (0.458)	-0.045 (0.433)	0.595	0.782
circ_0002968	499	3123	MAPK8	Ubiquitous, highly enriched in the cerebellum	-0.047 (0.361)	-0.087 (0.476)	0.603	0.782
circ_0000396	522	3086	SLC38A1	Ubiquitous	-0.097 (0.498)	-0.237 (0.472)	0.115	0.380
circ_0001181	1836	3082	BACH1	ubiquitous, expressed least in the brain	-0.203 (0.691)	-0.399 (0.538)	0.086	0.344
circ_0006916	522	3026	HOMER1	Ubiquitous, enriched in the brain	-0.076 (0.452)	-0.292 (0.316)	0.003**	0.036*
circ_0001709	212	2889	GBAS	Ubiquitous, highly enriched in the skeletal muscle	-0.047 (0.354)	-0.060 (0.359)	0.839	0.857
circ_0001897	158	2882	POMT1	Ubiquitous, highly enriched in the cerebellum and testis	-0.069 (0.426)	-0.139 (0.439)	0.375	0.667
circ_0101874	502	2687	FKBP3	Ubiquitous, enriched in the brain	-0.059 (0.395)	-0.136 (0.482)	0.347	0.640
circ_0002454	350	2511	DNAJC6	Brain-specific	-0.247 (0.728)	-0.027 (0.806)	0.119	0.380
circ_0001558	397	2476	UIMC1	Ubiquitous, expressed least in the brain except cerebellum where expression is similar to other tissues	-0.095 (0.498)	0.028 (0.497)	0.459	0.711

circ_0001187	301	2263	DOP1B	Ubiquitous, highly enriched in the cerebellum	-0.071 (0.440)	-0.265 (0.282)	0.005**	0.038*
circ_0006508	440	2229	VMP1	Ubiquitous, expressed least in the brain	-0.058 (0.384)	-0.031 (0.402)	0.711	0.812
circ_0006677	473	2190	WDR78	Testis, lung	-0.072 (0.439)	-0.051 (0.492)	0.801	0.850
circ_0008032	302	2153	HAT1	Ubiquitous, expressed least in the brain	-0.133 (0.579)	-0.204 (0.526)	0.482	0.723
circ_0043837	444	1892	ATP6V0A1	Ubiquitous, highly enriched in the brain	-0.142 (0.611)	-0.250 (0.597)	0.334	0.640
circ_0004368	352	1882	REPS1	Ubiquitous, highly enriched in the cerebellum	-0.076 (0.455)	-0.299 (0.313)	0.002**	0.036*
circ_0005315	308	1820	KIDINS220	Ubiquitous, enriched in the cerebellum	-0.149 (0.554)	-0.194 (0.438)	0.628	0.793
circ_0002058	248	1775	TMEM138	ubiquitous, expressed least in the brain	-0.055 (0.379)	0.028 (0.465)	0.286	0.603
circ_0001566	497	1745	MAPK9	Ubiquitous, enriched in the brain	-0.066 (0.425)	-0.284 (0.352)	0.002**	0.036*
circ_0007793	284	1645	KIAA1841	Ubiquitous, somewhat brain-enriched	-0.141 (0.591)	-0.168 (0.556)	0.793	0.850
circ_0001340	251	1631	TMCC1	Ubiquitous, enriched in the cerebellum	-0.054 (0.380)	-0.108 (0.389)	0.443	0.711
circ_0007162	1121	1526	AGTPBP1	Ubiquitous, somewhat brain-enriched	-0.103 (0.524)	-0.317 (0.434)	0.017*	0.113
circ_0003848	222	1430	PSEN1	Ubiquitous, highly enriched in the spinal cord	-0.054 (0.388)	-0.241 (0.308)	0.004**	0.038*
circ_0004058	370	1422	ZNF292	Ubiquitous, expressed least in the brain except cerebellum where expression is similar to other tissues	-0.095 (0.491)	-0.045 (0.479)	0.577	0.782
circ_0001875	556	1345	FAM120A	Ubiquitous, expressed least in the brain	-0.098 (0.504)	-0.196 (0.500)	0.289	0.603
circ_0003028	430	1336	FUT8	Ubiquitous, highly enriched in the spinal cord	-0.270 (0.792)	-0.309 (0.654)	0.850	0.850
circ_0001839	292	1280	KDM4C	Ubiquitous, highly enriched in the cerebellum	-0.066 (0.418)	-0.115 (0.482)	0.557	0.782
circ_0001392	484	1270	HTT	Ubiquitous, enriched in the cerebellum	-0.060 (0.384)	-0.019 (0.453)	0.602	0.782
circ_0067735	457	952	MED12L	Adrenal glands, brain, cervix, pituitary and testis	-0.477 (1.100)	-0.124 (1.202)	0.096	0.354
circ_0000643	381	761	ZFAND6	Ubiquitous, expressed least in the brain	-0.090 (0.477)	-0.173 (0.467)	0.341	0.640
circ_0126525	971	720	SLAIN2	Ubiquitous, expressed least in the brain	-0.075 (0.450)	0.125 (0.628)	0.048*	0.210
circ_0001359	505	709	PHC3	Ubiquitous, expressed least in the brain	-0.060 (0.403)	-0.118 (0.434)	0.454	0.711

481 *According to Rybak et al.

482 ** According to GTEx portal.

483

484 **Supplemental Table 4. Correlation between relative circRNA expression and sex, age, age-**

485 **at-onset, PD duration, HY, UPDRS and MMSE scores and LEDD of PD patients.**

486

circRNA	Sex U score (P value)	Age Rho (P value)	Age-at- onset Rho (P value)	PD duration Rho (P value)	UPDRS III Rho (P value)	MMSE Rho (P value)	HY Rho (P value)	LEDD Rho (P value)
UBXN7_circ _0001380	0.027 (0.8684)	-0.012 (0.8949)	-0.142 (0.2831)	0.041 (0.7579)	0.143 (0.2788)	0.096 (0.4674)	0.113 (0.3953)	0.055 (0.6791)
HIPK3_circ _0000284	1.694 (0.1930)	0.004 (0.9627)	-0.129 (0.3266)	-0.063 (0.6303)	-0.036 (0.7847)	0.090 (0.4924)	-0.052 (0.6943)	0.100 (0.4450)
SMARCA5_ circ_0001445	0.778 (0.3776)	-0.035 (0.7078)	-0.119 (0.3663)	-0.174 (0.1847)	0.018 (0.8931)	0.082 (0.5321)	0.005 (0.9704)	0.006 (0.9643)
EXO6CB_circ _0009043	1.129 (0.2880)	0.142 (0.1215)	0.225 (0.0836)	-0.116 (0.3793)	-0.014 (0.9165)	-0.021 (0.8736)	-0.066 (0.6187)	-0.024 (0.8551)
AFF2_circ _0001947	0.011 (0.9159)	0.107 (0.2446)	0.101 (0.4418)	-0.036 (0.7871)	0.050 (0.7055)	-0.048 (0.7130)	-0.138 (0.2917)	0.156 (0.2334)
UBE2K_circ _0002590	0.010 (0.9208)	-0.035 (0.7022)	-0.143 (0.2773)	-0.187 (0.1535)	-0.167 (0.2024)	0.065 (0.6205)	-0.012 (0.9295)	-0.139 (0.2898)
CORO1C_circ _0000437	0.035 (0.8521)	-0.089 (0.3313)	-0.390 (0.0021)	0.211 (0.1050)	0.090 (0.4928)	0.039 (0.7691)	0.019 (0.8856)	0.183 (0.1618)
SLAIN1_circ _0000497	0.026 (0.8717)	-0.098 (0.2870)	-0.085 (0.5188)	-0.109 (0.4071)	0.094 (0.4771)	0.257 (0.0472)	0.132 (0.3146)	0.050 (0.7061)
RTN4_circ _0054598	3.005 (0.0830)	0.035 (0.7015)	-0.203 (0.1191)	-0.073 (0.5807)	-0.033 (0.8049)	0.077 (0.5578)	-0.016 (0.9048)	0.027 (0.8353)
CSNK1G3_ circ_0001522	3.347 (0.0673)	-0.049 (0.5978)	0.083 (0.5300)	-0.217 (0.0987)	-0.018 (0.8931)	0.172 (0.1924)	-0.088 (0.5066)	-0.115 (0.3837)
R3HDM1_ circ_0001070	0.078 (0.7798)	0.010 (0.9160)	0.033 (0.8001)	-0.127 (0.3322)	-0.224 (0.0850)	0.061 (0.6445)	-0.156 (0.2326)	-0.153 (0.2434)
ZMYM4_circ _0011536	3.556 (0.0593)	-0.085 (0.3584)	-0.044 (0.7413)	-0.341 (0.0078)	-0.123 (0.3479)	0.122 (0.3540)	0.000 (0.9976)	-0.081 (0.5403)

VPS13C_circ_0000607	0.001 (0.9802)	0.049 (0.5951)	0.018 (0.8923)	-0.048 (0.7134)	-0.073 (0.5790)	-0.204 (0.1181)	0.090 (0.4930)	-0.058 (0.6610)
SCLT1_circ_0001439	0.028 (0.8668)	0.016 (0.8636)	-0.159 (0.2264)	-0.037 (0.7774)	0.094 (0.4769)	0.048 (0.7169)	0.055 (0.6761)	0.184 (0.1589)
ANKRD12_circ_0000826	0.285 (0.5931)	0.008 (0.9346)	-0.091 (0.4876)	0.016 (0.9014)	0.090 (0.4944)	-0.023 (0.8612)	0.165 (0.2071)	0.116 (0.3755)
SFMBT2_circ_0000211	0.519 (0.4711)	0.100 (0.2778)	0.008 (0.9543)	-0.114 (0.3873)	0.053 (0.6898)	0.244 (0.0598)	0.092 (0.4864)	0.003 (0.9828)
LRCH3_circ_0002266	0.556 (0.4559)	-0.042 (0.6471)	-0.094 (0.4739)	-0.236 (0.0692)	-0.104 (0.4283)	0.087 (0.5074)	0.070 (0.5965)	-0.061 (0.6453)
MAPK8_circ_0002968	0.846 (0.3578)	-0.064 (0.4898)	0.037 (0.7785)	-0.163 (0.2146)	0.040 (0.7634)	0.096 (0.4648)	0.115 (0.3814)	-0.090 (0.4943)
SLC38A1_circ_0000396	0.062 (0.8037)	-0.111 (0.2284)	0.207 (0.1124)	-0.149 (0.2565)	0.024 (0.8558)	0.087 (0.5068)	0.004 (0.9766)	-0.135 (0.3040)
BACH1_circ_0001181	3.978 (0.0461)	-0.133 (0.1488)	-0.110 (0.4034)	-0.028 (0.8333)	0.070 (0.5948)	0.070 (0.5932)	0.066 (0.6146)	0.254 (0.0498)
HOMER1_circ_0006916	0.102 (0.7490)	-0.112 (0.2253)	-0.040 (0.7623)	-0.090 (0.4928)	0.099 (0.4499)	0.068 (0.6068)	0.157 (0.2318)	0.032 (0.8105)
GBAS_circ_0001709	0.892 (0.3450)	-0.041 (0.6604)	-0.066 (0.6138)	-0.001 (0.9951)	0.111 (0.4003)	0.201 (0.1244)	0.185 (0.1566)	0.025 (0.8487)
POMT1_circ_0001897	1.293 (0.2555)	0.032 (0.7285)	0.002 (0.9851)	-0.130 (0.3239)	-0.006 (0.9630)	-0.095 (0.4723)	0.012 (0.9301)	-0.011 (0.9336)
FKBP3_circ_0101874	0.030 (0.8633)	-0.073 (0.4314)	-0.009 (0.9472)	-0.142 (0.2839)	0.104 (0.4318)	0.111 (0.4040)	0.016 (0.9041)	0.050 (0.7091)
DNAJC6_circ_0002454	0.575 (0.4485)	-0.107 (0.2443)	-0.379 (0.0028)	0.000 (0.9985)	-0.011 (0.9352)	0.019 (0.8864)	-0.008 (0.9514)	0.078 (0.5516)
U1MC1_circ_0001558	2.384 (0.1226)	-0.010 (0.9113)	-0.070 (0.5960)	-0.223 (0.0868)	-0.181 (0.1657)	0.083 (0.5273)	-0.104 (0.4310)	-0.035 (0.7909)
DOP1B_circ_0001187	0.812 (0.3676)	-0.035 (0.7063)	0.020 (0.8778)	-0.101 (0.4416)	-0.147 (0.2623)	-0.075 (0.5711)	-0.156 (0.2354)	-0.267 (0.0396)
VMP1_circ_0006508	0.785 (0.3756)	-0.071 (0.4460)	-0.188 (0.1534)	-0.123 (0.3538)	-0.053 (0.6923)	0.166 (0.2081)	0.046 (0.7298)	-0.112 (0.3980)
WDR78_circ_0006677	0.547 (0.4596)	-0.086 (0.3541)	-0.252 (0.0545)	-0.074 (0.5794)	-0.037 (0.7812)	0.071 (0.5919)	0.044 (0.7407)	0.001 (0.9918)
HAT1_circ_0008032	4.783 (0.0287)	-0.039 (0.6710)	-0.098 (0.4550)	-0.131 (0.3176)	0.018 (0.8914)	0.100 (0.4488)	0.138 (0.2922)	0.030 (0.8196)

ATP6V0A1_circ_0043837	0.010 (0.9208)	0.048 (0.6025)	-0.111 (0.3978)	0.095 (0.4719)	-0.001 (0.9958)	-0.008 (0.9523)	-0.072 (0.5843)	0.070 (0.5971)
REPS1_circ_0004368	0.363 (0.5467)	0.012 (0.8933)	0.108 (0.4099)	-0.206 (0.1135)	-0.009 (0.9453)	-0.148 (0.2587)	-0.023 (0.8642)	-0.054 (0.6831)
KIDINS220_circ_0005315	4.019 (0.0450)	0.010 (0.9103)	-0.093 (0.4845)	-0.076 (0.5681)	0.058 (0.6643)	0.227 (0.0833)	0.036 (0.7864)	0.020 (0.8785)
TMEM138_circ_0002058	0.020 (0.8864)	0.032 (0.7304)	-0.008 (0.9521)	-0.030 (0.8227)	0.014 (0.9144)	-0.043 (0.7471)	0.068 (0.6034)	0.030 (0.8221)
MAPK9_circ_0001566	1.954 (0.1621)	0.044 (0.6357)	-0.119 (0.3663)	0.063 (0.6301)	0.062 (0.6389)	0.202 (0.1208)	0.057 (0.6662)	-0.010 (0.9406)
KIAA1841_circ_0007793	0.034 (0.8546)	-0.014 (0.8824)	-0.179 (0.1715)	-0.027 (0.8372)	0.089 (0.4983)	0.025 (0.8473)	0.050 (0.7058)	0.244 (0.0601)
TMCC1_circ_0001340	0.053 (0.8185)	-0.006 (0.9453)	-0.104 (0.4335)	-0.049 (0.7133)	0.026 (0.8473)	0.093 (0.4816)	0.045 (0.7331)	0.049 (0.7141)
AGTPBP1_circ_0007162	0.068 (0.7941)	0.033 (0.7198)	-0.047 (0.7215)	-0.076 (0.5616)	0.168 (0.1995)	0.156 (0.2330)	0.110 (0.4023)	0.264 (0.0413)
PSEN1_circ_0003848	0.148 (0.7001)	0.002 (0.9865)	-0.263 (0.0424)	0.012 (0.9249)	0.077 (0.5594)	0.160 (0.2218)	0.010 (0.9394)	0.244 (0.0606)
ZNF292_circ_0004058	0.121 (0.7283)	-0.020 (0.8305)	-0.089 (0.5008)	-0.232 (0.0770)	-0.022 (0.8662)	0.077 (0.5620)	-0.038 (0.7733)	-0.074 (0.5774)
FAM120A_circ_0001875	0.047 (0.8279)	-0.082 (0.3747)	-0.237 (0.0687)	-0.145 (0.2675)	-0.070 (0.5942)	0.129 (0.3253)	-0.041 (0.7551)	-0.009 (0.9473)
FUT8_circ_0003028	0.493 (0.4826)	-0.074 (0.4238)	-0.214 (0.1004)	0.029 (0.8233)	-0.040 (0.7600)	0.072 (0.5852)	-0.094 (0.4761)	-0.114 (0.3875)
KDM4C_circ_0001839	0.030 (0.8619)	0.070 (0.4462)	0.122 (0.3525)	-0.183 (0.1627)	-0.177 (0.1753)	0.069 (0.6028)	-0.153 (0.2436)	-0.121 (0.3555)
HTT_circ_0001392	1.317 (0.2512)	-0.092 (0.3232)	-0.045 (0.7327)	-0.101 (0.4470)	0.078 (0.5564)	0.118 (0.3754)	0.054 (0.6859)	-0.006 (0.9664)
MED12L_circ_0067735	1.103 (0.2937)	-0.137 (0.1368)	-0.415 (0.0010)	0.221 (0.0893)	0.066 (0.6178)	0.050 (0.7037)	0.008 (0.9512)	0.246 (0.0580)
ZFAND6_circ_0000643	4.280 (0.0386)	-0.053 (0.5659)	-0.138 (0.2939)	-0.148 (0.2585)	-0.046 (0.7246)	0.098 (0.4573)	-0.029 (0.8284)	-0.108 (0.4101)
SLAIN2_circ_0126525	0.623 (0.4301)	0.015 (0.8669)	-0.060 (0.6462)	-0.135 (0.3030)	-0.100 (0.4489)	0.096 (0.4651)	-0.043 (0.7458)	-0.039 (0.7653)
PHC3_circ_0001359	0.418 (0.5182)	-0.003 (0.9738)	-0.064 (0.6282)	-0.217 (0.0951)	-0.068 (0.6062)	0.139 (0.2897)	-0.037 (0.7778)	-0.077 (0.5598)

487
 488 **Significance Supplemental Table 5. KEGG and GOslim categories that are mostly**
 489 **deregulated in idiopathic PD.** Gene union of the targets of the five miRNAs (miR-516b-5p, miR-
 490 526b-5p, miR-578, miR-659-3p, miR-1197) sequestered by half or more of the deregulated PD
 491 circRNAs in PD versus (A) KEGG and (B) GOslim categories created by the DIANA-miRPath
 492 v3.0 interface using default values (*p*-value threshold 0.05, microT-CDS threshold 0.8).

493
 494 **A**

KEGG pathway	<i>P</i> value	# genes	# miRNAs
Thyroid hormone signaling pathway	0.001458	24	5
Cell cycle	0.009263	25	5
Regulation of actin cytoskeleton	0.014546	42	5
Rap1 signaling pathway	0.01546	35	5
Phosphatidylinositol signaling system	0.015883	16	4
MAPK signaling pathway	0.015883	46	5
FoxO signaling pathway	0.015883	26	5

495
 496
 497 **B**
 498

GOslim category	<i>P</i> value	# genes	# miRNAs
Organelle	1.13E-78	1143	5
Cellular nitrogen compound metabolic process	6.05E-47	587	5
Cellular protein modification process	3.93E-19	283	5
Nucleoplasm	2.34E-13	159	5
Enzyme binding	2.34E-13	168	5

Protein complex	4.38E-11	411	5
Protein binding transcription factor activity	6.74E-10	70	5
Cytoskeletal protein binding	3.91E-09	102	5
Cell death	7.91E-08	112	5
RNA binding	6.93E-07	207	5
Nucleic acid binding transcription factor activity	7.74E-07	112	5
Macromolecular complex assembly	3.06E-05	95	5
Response to stress	3.72E-05	225	5
Membrane organization	4.89E-05	65	5
Cytoskeleton organization	0.000178	80	5

499

500 REFERENCES

- 501 1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's
502 disease. *Movement disorders : official journal of the Movement Disorder Society*
503 2015;30(12):1591-1601.
- 504 2. Bhidayasiri R, Martinez-Martin P. Clinical Assessments in Parkinson's Disease: Scales and
505 Monitoring. *International review of neurobiology* 2017;132:129-182.
- 506 3. Miller DB, O'Callaghan JP. Biomarkers of Parkinson's disease: present and future.
507 *Metabolism: clinical and experimental* 2015;64(3 Suppl 1):S40-46.
- 508 4. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs
509 with regulatory potency. *Nature* 2013;495(7441):333-338.
- 510 5. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant
511 transcript isoform from hundreds of human genes in diverse cell types. *PloS one* 2012;7(2):e30733.

- 512 6. Zaphiropoulos PG. Circular RNAs from transcripts of the rat cytochrome P450 2C24 gene:
513 correlation with exon skipping. *Proceedings of the National Academy of Sciences of the United*
514 *States of America* 1996;93(13):6536-6541.
- 515 7. Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and
516 associated with ALU repeats. *Rna* 2013;19(2):141-157.
- 517 8. Schwanhausser B, Busse D, Li N, et al. Global quantification of mammalian gene
518 expression control. *Nature* 2011;473(7347):337-342.
- 519 9. Abdelmohsen K, Panda AC, Munk R, et al. Identification of HuR target circular RNAs
520 uncovers suppression of PABPN1 translation by CircPABPN1. *RNA biology* 2017;14(3):361-369.
- 521 10. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient
522 microRNA sponges. *Nature* 2013;495(7441):384-388.
- 523 11. Zimmerman AJ, Hafez AK, Amoah SK, et al. A psychiatric disease-related circular RNA
524 controls synaptic gene expression and cognition. *Molecular psychiatry* 2020.
- 525 12. Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the
526 nucleus. *Nature structural & molecular biology* 2015;22(3):256-264.
- 527 13. Zhang Y, Zhang XO, Chen T, et al. Circular intronic long noncoding RNAs. *Molecular*
528 *cell* 2013;51(6):792-806.
- 529 14. Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-
530 mRNA splicing. *Molecular cell* 2014;56(1):55-66.
- 531 15. Koh W, Gonzalez V, Natarajan S, Carter R, Brown PO, Gawad C. Dynamic ASXL1 Exon
532 Skipping and Alternative Circular Splicing in Single Human Cells. *PloS one*
533 2016;11(10):e0164085.

- 534 16. You X, Vlatkovic I, Babic A, et al. Neural circular RNAs are derived from synaptic genes
535 and regulated by development and plasticity. *Nature neuroscience* 2015;18(4):603-610.
- 536 17. Mahmoudi E, Cairns MJ. Circular RNAs are temporospatially regulated throughout
537 development and ageing in the rat. *Scientific reports* 2019;9(1):2564.
- 538 18. Rybak-Wolf A, Stottmeister C, Glazar P, et al. Circular RNAs in the Mammalian Brain
539 Are Highly Abundant, Conserved, and Dynamically Expressed. *Molecular cell* 2015;58(5):870-
540 885.
- 541 19. Mehta SL, Dempsey RJ, Vemuganti R. Role of circular RNAs in brain development and
542 CNS diseases. *Progress in neurobiology* 2020;186:101746.
- 543 20. Lukiw WJ. Circular RNA (circRNA) in Alzheimer's disease (AD). *Frontiers in genetics*
544 2013;4:307.
- 545 21. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-
546 153. *The Journal of biological chemistry* 2010;285(17):12726-12734.
- 547 22. Zhao Y, Alexandrov PN, Jaber V, Lukiw WJ. Deficiency in the Ubiquitin Conjugating
548 Enzyme UBE2A in Alzheimer's Disease (AD) is Linked to Deficits in a Natural Circular miRNA-
549 7 Sponge (circRNA; ciRS-7). *Genes* 2016;7(12).
- 550 23. Hanan M, Simchovitz A, Yayon N, et al. A Parkinson's disease CircRNAs Resource reveals
551 a link between circSLC8A1 and oxidative stress. *EMBO molecular medicine* 2020:e11942.
- 552 24. Paschou M, Doxakis E. Neurofibromin 1 Is a miRNA Target in Neurons. *PloS one*
553 2012;7(10):e46773.
- 554 25. Paschou M, Maier L, Papazafiri P, et al. Neuronal microRNAs modulate TREK two-pore
555 domain K(+) channel expression and current density. *RNA biology* 2020;17(5):651-662.

- 556 26. Tan CL, Plotkin JL, Veno MT, et al. MicroRNA-128 governs neuronal excitability and
557 motor behavior in mice. *Science* 2013;342(6163):1254-1258.
- 558 27. Zhang W, Kim PJ, Chen Z, et al. MiRNA-128 regulates the proliferation and neurogenesis
559 of neural precursors by targeting PCMI in the developing cortex. *eLife* 2016;5.
- 560 28. Iturria-Medina Y, Khan AF, Adewale Q, Shirazi AH, Alzheimer's Disease Neuroimaging
561 I. Blood and brain gene expression trajectories mirror neuropathology and clinical deterioration in
562 neurodegeneration. *Brain : a journal of neurology* 2020;143(2):661-673.
- 563 29. Naughton BJ, Duncan FJ, Murrey DA, et al. Blood genome-wide transcriptional profiles
564 reflect broad molecular impairments and strong blood-brain links in Alzheimer's disease. *Journal*
565 *of Alzheimer's disease : JAD* 2015;43(1):93-108.
- 566 30. Pinho R, Guedes LC, Soreq L, et al. Gene Expression Differences in Peripheral Blood of
567 Parkinson's Disease Patients with Distinct Progression Profiles. *PloS one* 2016;11(6):e0157852.
- 568 31. Soreq L, Bergman H, Israel Z, Soreq H. Exon arrays reveal alternative splicing aberrations
569 in Parkinson's disease leukocytes. *Neuro-degenerative diseases* 2012;10(1-4):203-206.
- 570 32. van Heerden JH, Conesa A, Stein DJ, Montaner D, Russell V, Illing N. Parallel changes in
571 gene expression in peripheral blood mononuclear cells and the brain after maternal separation in
572 the mouse. *BMC research notes* 2009;2:195.
- 573 33. Soreq L, Salomonis N, Bronstein M, et al. Small RNA sequencing-microarray analyses in
574 Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain
575 region transcriptomes. *Frontiers in molecular neuroscience* 2013;6:10.
- 576 34. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia:
577 recommendations from the movement disorder society task force. *Movement disorders : official*
578 *journal of the Movement Disorder Society* 2007;22(16):2314-2324.

- 579 35. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of
580 levodopa dose equivalency reporting in Parkinson's disease. *Movement disorders : official journal*
581 *of the Movement Disorder Society* 2010;25(15):2649-2653.
- 582 36. Maass PG, Glazar P, Memczak S, et al. A map of human circular RNAs in clinically
583 relevant tissues. *Journal of molecular medicine* 2017;95(11):1179-1189.
- 584 37. Dube U, Del-Aguila JL, Li Z, et al. An atlas of cortical circular RNA expression in
585 Alzheimer disease brains demonstrates clinical and pathological associations. *Nature neuroscience*
586 2019;22(11):1903-1912.
- 587 38. Gokool A, Anwar F, Voineagu I. The Landscape of Circular RNA Expression in the
588 Human Brain. *Biological psychiatry* 2020;87(3):294-304.
- 589 39. Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M.
590 CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and
591 microRNAs. *RNA biology* 2016;13(1):34-42.
- 592 40. Xia S, Feng J, Chen K, et al. CSCD: a database for cancer-specific circular RNAs. *Nucleic*
593 *acids research* 2018;46(D1):D925-D929.
- 594 41. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-
595 ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. *Nucleic acids*
596 *research* 2014;42(Database issue):D92-97.
- 597 42. Vlachos IS, Zagganas K, Paraskevopoulou MD, et al. DIANA-miRPath v3.0: deciphering
598 microRNA function with experimental support. *Nucleic acids research* 2015;43(W1):W460-466.
- 599 43. Ravanidis S, Bougea A, Papagiannakis N, et al. Circulating Brain-enriched MicroRNAs
600 for detection and discrimination of idiopathic and genetic Parkinson's disease. *Movement disorders*
601 *: official journal of the Movement Disorder Society* 2020;35(3):457-467.

- 602 44. Dzamko N, Zhou J, Huang Y, Halliday GM. Parkinson's disease-implicated kinases in the
603 brain; insights into disease pathogenesis. *Frontiers in molecular neuroscience* 2014;7:57.
- 604 45. Waetzig V, Zhao Y, Herdegen T. The bright side of JNKs-Multitalented mediators in
605 neuronal sprouting, brain development and nerve fiber regeneration. *Progress in neurobiology*
606 2006;80(2):84-97.
- 607 46. Jardin I, Lopez JJ, Berna-Erro A, Salido GM, Rosado JA. Homer proteins in Ca(2)(+)
608 entry. *IUBMB life* 2013;65(6):497-504.
- 609 47. De Luca V, Annesi G, De Marco EV, et al. HOMER1 promoter analysis in Parkinson's
610 disease: association study with psychotic symptoms. *Neuropsychobiology* 2009;59(4):239-245.
- 611 48. van der Vaart B, Franker MA, Kuijpers M, et al. Microtubule plus-end tracking proteins
612 SLAIN1/2 and ch-TOG promote axonal development. *The Journal of neuroscience : the official*
613 *journal of the Society for Neuroscience* 2012;32(42):14722-14728.
- 614 49. Harripaul R, Vasli N, Mikhailov A, et al. Mapping autosomal recessive intellectual
615 disability: combined microarray and exome sequencing identifies 26 novel candidate genes in 192
616 consanguineous families. *Molecular psychiatry* 2018;23(4):973-984.
- 617 50. McGough IJ, de Groot REA, Jellett AP, et al. SNX3-retromer requires an evolutionary
618 conserved MON2:DOPEY2:ATP9A complex to mediate Wntless sorting and Wnt secretion.
619 *Nature communications* 2018;9(1):3737.
- 620 51. Zhao SB, Dean N, Gao XD, Fujita M. MON2 Guides Wntless Transport to the Golgi
621 through Recycling Endosomes. *Cell structure and function* 2020;45(1):77-92.
- 622 52. Lopes C, Chettouh Z, Delabar JM, Rachidi M. The differentially expressed C21orf5 gene
623 in the medial temporal-lobe system could play a role in mental retardation in Down syndrome and
624 transgenic mice. *Biochemical and biophysical research communications* 2003;305(4):915-924.

- 625 53. Rachidi M, Delezoide AL, Delabar JM, Lopes C. A quantitative assessment of gene
626 expression (QAGE) reveals differential overexpression of DOPEY2, a candidate gene for mental
627 retardation, in Down syndrome brain regions. *International journal of developmental neuroscience*
628 : the official journal of the International Society for Developmental Neuroscience 2009;27(4):393-
629 398.
- 630 54. Swaminathan S, Huentelman MJ, Corneveaux JJ, et al. Analysis of copy number variation
631 in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified
632 individuals. *PloS one* 2012;7(12):e50640.
- 633 55. Swaminathan S, Shen L, Kim S, et al. Analysis of copy number variation in Alzheimer's
634 disease: the NIALOAD/ NCRAD Family Study. *Current Alzheimer research* 2012;9(7):801-814.
- 635 56. Dergai O, Novokhatska O, Dergai M, et al. Intersectin 1 forms complexes with SGIP1 and
636 Repl1 in clathrin-coated pits. *Biochemical and biophysical research communications*
637 2010;402(2):408-413.
- 638 57. Drecourt A, Babdor J, Dussiot M, et al. Impaired Transferrin Receptor Palmitoylation and
639 Recycling in Neurodegeneration with Brain Iron Accumulation. *American journal of human*
640 *genetics* 2018;102(2):266-277.
- 641 58. Bagyinszky E, Youn YC, An SS, Kim S. The genetics of Alzheimer's disease. *Clinical*
642 *interventions in aging* 2014;9:535-551.
- 643 59. Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in
644 brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid
645 precursor protein genes. *The American journal of pathology* 1998;153(5):1365-1370.
- 646 60. Deaton CA, Johnson GVW. Presenilin 1 Regulates Membrane Homeostatic Pathways that
647 are Dysregulated in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD* 2020.

- 648 61. Gatto EM, Rojas GJ, Nemirovsky SI, et al. A novel mutation in PSEN1 (p.Arg41Ser) in an
649 Argentinian woman with early onset Parkinsonism. *Parkinsonism & related disorders* 2020;77:21-
650 25.
- 651 62. Ravanidis S, Bougea A, Papagiannakis N, et al. Validation of differentially expressed
652 brain-enriched microRNAs in the plasma of PD patients. *Annals of clinical and translational*
653 *neurology* 2020.
- 654 63. Abramzon YA, Fratta P, Traynor BJ, Chia R. The Overlapping Genetics of Amyotrophic
655 Lateral Sclerosis and Frontotemporal Dementia. *Frontiers in neuroscience* 2020;14:42.
- 656 64. Doxakis E. RNA binding proteins: a common denominator of neuronal function and
657 dysfunction. *Neuroscience bulletin* 2014;30(4):610-626.
- 658 65. Egorova PA, Bezprozvanny IB. Molecular Mechanisms and Therapeutics for
659 Spinocerebellar Ataxia Type 2. *Neurotherapeutics : the journal of the American Society for*
660 *Experimental NeuroTherapeutics* 2019;16(4):1050-1073.
- 661 66. Ravanidis S, Doxakis E. RNA-Binding Proteins Implicated in Mitochondrial Damage and
662 Mitophagy. *Frontiers in cell and developmental biology* 2020;8:372.
- 663 67. Ravanidis S, Kattan FG, Doxakis E. Unraveling the Pathways to Neuronal Homeostasis
664 and Disease: Mechanistic Insights into the Role of RNA-Binding Proteins and Associated Factors.
665 *International journal of molecular sciences* 2018;19(8).
- 666 68. Salcedo-Arellano MJ, Dufour B, McLennan Y, Martinez-Cerdeno V, Hagerman R. Fragile
667 X syndrome and associated disorders: Clinical aspects and pathology. *Neurobiology of disease*
668 2020;136:104740.
- 669 69. Kim JM, Hong S, Kim GP, et al. Importance of low-range CAG expansion and CAA
670 interruption in SCA2 Parkinsonism. *Archives of neurology* 2007;64(10):1510-1518.

- 671 70. Wang C, Xu Y, Feng X, et al. Linkage analysis and whole-exome sequencing exclude extra
672 mutations responsible for the parkinsonian phenotype of spinocerebellar ataxia-2. *Neurobiology*
673 of aging 2015;36(1):545 e541-547.
- 674 71. Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism
675 in ethnic Chinese. *Neurology* 2000;55(6):800-805.
- 676 72. Furtado S, Payami H, Lockhart PJ, et al. Profile of families with parkinsonism-predominant
677 spinocerebellar ataxia type 2 (SCA2). *Movement disorders : official journal of the Movement*
678 *Disorder Society* 2004;19(6):622-629.
- 679 73. Martens LH, Zhang J, Barmada SJ, et al. Progranulin deficiency promotes
680 neuroinflammation and neuron loss following toxin-induced injury. *The Journal of clinical*
681 *investigation* 2012;122(11):3955-3959.
- 682 74. Piscopo P, Grasso M, Fontana F, et al. Reduced miR-659-3p Levels Correlate with
683 Progranulin Increase in Hypoxic Conditions: Implications for Frontotemporal Dementia. *Frontiers*
684 *in molecular neuroscience* 2016;9:31.
- 685 75. Rademakers R, Eriksen JL, Baker M, et al. Common variation in the miR-659 binding-site
686 of GRN is a major risk factor for TDP43-positive frontotemporal dementia. *Human molecular*
687 *genetics* 2008;17(23):3631-3642.
- 688 76. Xu J, Xilouri M, Bruban J, et al. Extracellular progranulin protects cortical neurons from
689 toxic insults by activating survival signaling. *Neurobiology of aging* 2011;32(12):2326 e2325-
690 2316.
- 691 77. Yin F, Banerjee R, Thomas B, et al. Exaggerated inflammation, impaired host defense, and
692 neuropathology in progranulin-deficient mice. *The Journal of experimental medicine*
693 2010;207(1):117-128.

- 694 78. Bucher M, Fanutza T, Mikhaylova M. Cytoskeletal makeup of the synapse: Shaft versus
695 spine. *Cytoskeleton* 2020;77(3-4):55-64.
- 696 79. Pinho J, Marcut C, Fonseca R. Actin remodeling, the synaptic tag and the maintenance of
697 synaptic plasticity. *IUBMB life* 2020;72(4):577-589.
- 698 80. Rai SN, Dilnashin H, Birla H, et al. The Role of PI3K/Akt and ERK in Neurodegenerative
699 Disorders. *Neurotoxicity research* 2019;35(3):775-795.
- 700 81. Santo EE, Paik J. FOXO in Neural Cells and Diseases of the Nervous System. *Current*
701 *topics in developmental biology* 2018;127:105-118.
- 702 82. Junqueira SC, Centeno EGZ, Wilkinson KA, Cimarosti H. Post-translational modifications
703 of Parkinson's disease-related proteins: Phosphorylation, SUMOylation and Ubiquitination.
704 *Biochimica et biophysica acta Molecular basis of disease* 2019;1865(8):2001-2007.
- 705 83. Pajarillo E, Rizzor A, Lee J, Aschner M, Lee E. The role of posttranslational modifications
706 of alpha-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental
707 factors. *Biochimica et biophysica acta Molecular basis of disease* 2019;1865(8):1992-2000.
- 708 84. Calogero AM, Mazzetti S, Pezzoli G, Cappelletti G. Neuronal microtubules and proteins
709 linked to Parkinson's disease: a relevant interaction? *Biological chemistry* 2019;400(9):1099-1112.
- 710 85. Pellegrini L, Wetzel A, Granno S, Heaton G, Harvey K. Back to the tubule: microtubule
711 dynamics in Parkinson's disease. *Cellular and molecular life sciences : CMLS* 2017;74(3):409-
712 434.
- 713